Bardia on Sacituzumab Govitecan’s Current and Potential Future Position in TNBC

Welcome to OncLive On Air^®! I’m your host today, Jessica Hergert.

OncLive On Air^® is a podcast from OncLive^®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive^® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, sponsored by Gilead Sciences, we had the pleasure of speaking with Aditya Bardia, MD, MPH, an attending physician of Medical Oncology at Massachusetts General Hospital and an assistant professor of medicine at Harvard Medical School, to discuss the clinical experience with sacituzumab govitecan-hziy (Trodelvy) in metastatic triple-negative breast cancer (TNBC).

In April 2020, the TROP2-directed antibody and topoisomerase inhibitor drug conjugate received an accelerated approval for use in patients with metastatic TNBC who had received at least 2 prior therapies for metastatic disease based on data from a phase 1/2 trial of the agent.

In April 2021, the FDA granted a regular approval to sacituzumab govitecan for the treatment of patients with unresectable locally advanced or metastatic TNBC who have previously received 2 or more systemic therapies, at least 1 of them for metastatic disease.

Data from the confirmatory phase 3 ASCENT trial (NCT02574455) served as the basis for the full approval. Among all randomized patients, the median progression-free survival (PFS) with sacituzumab govitecan was 4.8 months (95% CI, 4.1-5.8) vs 1.7 months (95% CI, 1.5-2.5) with chemotherapy (HR 0.43; 95% CI, 0.35-0.54; P <.0001); this translated to a 57% reduction in the risk of disease worsening or death.

Moreover, the median overall survival (OS) was 11.8 months (95% CI, 10.5-13.8) and 6.9 months (95% CI, 5.9-7.6) in the investigative and control arms, respectively (HR 0.51; 95% CI, 0.41-0.62; P <.0001); this translated to a 49% reduction in the risk of death.

In our exclusive interview, Bardia discussed the role of sacituzumab govitecan in the treatment of patients with metastatic TNBC, the influence of the National Comprehensive Cancer Network guidelines on treatment recommendations and sequencing in the second-line setting, and ongoing research with the agent in the neoadjuvant setting.

Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field. For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air^®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air^®.

*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.